Beth Israel Deaconess Medical Center
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to Be Presented at the America Heart Association (AHA) Scientific Sessions 2017
Yahoo Finance · November 07, 2017
...n Number: VA.AOS.829 Session Title: Best in Show Vascular Disease and Thrombosis Science Presenter: Gerald Chi, M.D., PERFUSE Study Group, Beth Israel Deaconess Medical Center, Boston Presentation Date and Time...
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017
Benzinga · August 21, 2017
...PEX trial substudy Poster #: P4316 Poster Session: Session 5, Stroke and Carotid disease Presenter: Gerald Chi, M.D., Beth Israel Deaconess Medical Center, Boston Presentation Date and Time: August 28, 2017 fro...
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
MilTech · November 14, 2016
...inpatient and outpatient care, and pharmacy use. Lastly, in a poster session tomorrow, November 15, Gerald Chi, M.D., of the PERFUSE Study Group, will present results from a third retrospective APEX substudy. T...